Wed, June 17, 2026
AUS Edition NZ Edition UK Edition
CA Edition USA Edition IND Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. KURA
Healthcare
Facebook Twitter Linkedin

Kura Oncology Inc (NASDAQ:KURA)

9.24 USD

-0.300 3.145%
Last Updated at: 2026-06-16T15:14:00Z

Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

12730 High Bluff Drive, San Diego, CA, United States, 92130

858 500 8800

https://kuraoncology.com

Employees: 142

Key Executives

Sr. No. Name Title Year Born
1. Dr. Troy Edward Wilson J.D., Ph.D. Chairman, CEO, Pres & Principal Financial Officer 1969
2. Ms. Kathleen Ford Chief Operating Officer 1947
3. Dr. Marc Grasso M.D. Advisor 1974
4. Ms. Kirsten Flowers Chief Commercial Officer & Chief Corp. Strategy Officer 1975
5. Dr. Stephen Dale M.D. Chief Medical Officer 1972
6. Mr. Thomas Doyle Principal Accounting Officer & Sr. VP of Fin. and Accounting 1971
7. Mr. Pete De Spain Sr. VP of Investor Relations & Corp. Communications NA
8. Mr. James E. Basta J.D., Esq. Chief Compliance Officer & Corp. Sec. 1966
9. Ms. Teresa Brophy Bair Esq., J.D. Chief Legal Officer & Corp. Sec. 1971
10. Dr. Roger Bakale Ph.D. VP and Head of CMC, Clinical & Commercial Manufacturing NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
NVO

Novo Nordisk A/S

 -0.425 0.968% 44.03 41.580 31.153 2.134 32.989 2.113 4.700
NONOF

Novo Nordisk A/S

 +0.001 0.003% 44.4 41.060 31.250 2.078 33.111 2.113 4.700
VRTX

Vertex Pharmaceuticals Inc

 -2.820 0.626% 451.255 29.670 24.331 10.385 5.832 9.334 20.004
REGN

Regeneron Pharmaceuticals Inc

 -3.105 0.505% 616.07 29.070 20.121 7.570 3.823 6.950 19.423

Income Statement

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Income Before Tax -135.84M -130.466M -89.625M -63.14M -60.447M
Minority Interest - - - - -
Net Income -136.069M -129.908M -89.431M -63.14M -60.447M
Selling General Administrative 47.053M 46.537M 31.502M 19.653M 16.096M
Gross Profit - - - - 0M
Reconciled Depreciation 0.759M 0.558M 0.194M 0M 0.01M
Ebit -140.624M -131.816M -92.093M -63.14M -62.893M
Ebitda -139.865M -131.258M -91.899M -67.479M -62.883M
Depreciation And Amortization 0.759M 0.558M 0.194M - 0.01M
Operating Income -140.624M -131.816M -92.093M -67.479M -62.883M
Other Operating Expenses 139.865M 131.258M 91.899M 67.479M 62.883M
Interest Expense 0.229M 0.414M 0.578M 0.58M 0.97M
Tax Provision - - - - -
Interest Income 4.254M 1.206M 2.801M 4.674M 3.169M
Net Interest Income 4.025M 0.792M 2.223M 4.094M 2.199M
Income Tax Expense 0.229M -0.558M -0.194M -4.919M 3.406M
Total Revenue 0M 0M 0M 0M 0M
Total Operating Expenses 139.865M 131.258M 91.899M 67.479M 62.883M
Cost Of Revenue - - - - 0M
Total Other Income Expense Net 4.784M 1.35M 2.468M 4.339M 2.436M
Net Income From Continuing Ops -135.84M -130.466M -89.625M -63.14M -60.447M
Net Income Applicable To Common Shares -135.84M -130.466M -89.625M -63.14M -60.447M

Balance Sheet

(Currency in USD)
Breakdown 31-12-2023 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Total Assets 448.935M 456.306M 534.051M 647.212M 241.972M
Intangible Assets - - - - -
Other Current Assets 5.724M 8.441M 4.329M 3.972M 2.682M
Total Liab 51.662M 36.028M 27.442M 36.307M 23.191M
Total Stockholder Equity 397.273M -568.808M -432.968M -302.502M -212.877M
Other Current Liab 31.457M 20.206M 16.956M 18.182M 11.788M
Common Stock 0.007M 0.007M 0.007M 0.007M 0.005M
Capital Stock 0.007M 0.007M 0.007M 0.007M 0.005M
Retained Earnings -721.439M -568.808M -432.968M -302.502M -212.877M
Good Will - - - - -
Other Assets - 3.498M 3.516M 7.899M 2.091M
Cash 37.318M 51.802M 90.672M 325.493M 26.135M
Cash And Equivalents - - - - -
Total Current Liabilities 35.263M 24.057M 22.455M 26.024M 15.564M
Current Deferred Revenue - - - - -
Net Debt -20.118M -37.778M -83.797M -310.516M -18.635M
Short Term Debt 1.506M 2.318M 2.263M 5.089M 0.25M
Short Long Term Debt - - - 3M 0.25M
Short Long Term Debt Total 17.2M 14.024M 6.875M 14.977M 7.5M
Other Stockholder Equity 1119.976M 8.025M 1.782M -0.053M -0.336M
Property Plant Equipment - 2.54M 2.673M 2.021M 0.278M
Total Current Assets 432.481M 446.426M 522.289M 637.292M 239.603M
Long Term Investments - - - - -
Short Term Investments 386.639M 386.183M 427.288M 307.827M 210.756M
Net Receivables 2.8M 0.9M 1.4M - 0.03M
Long Term Debt 9.332M 9.158M - 4.25M 7.25M
Inventory - - - - -
Accounts Payable 2.3M 1.533M 3.236M 2.753M 3.526M
Accumulated Other Comprehensive Income -1.271M -8.032M -1.789M 0.046M 0.331M
Non Currrent Assets Other 7.402M 3.498M 3.516M 1.565M 2.325M
Non Current Assets Total 16.454M 9.88M 11.762M 9.92M 2.369M
Capital Lease Obligations 7.868M 4.866M 6.875M 7.727M -
Long Term Debt Total - 9.158M - 4.25M 7.25M

Cash Flow

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019 31-12-2018
Investments 32.627M -125.688M -97.765M -46.325M -79.3M
Total Cashflows From Investing Activities 32.627M -126.835M -99.936M -46.325M -79.3M
Total Cash From Financing Activities 38.565M -3.435M 469.334M 111.101M 132.641M
Net Income -135.84M -130.466M -89.625M -63.14M -60.447M
Change In Cash -38.87M -234.821M 299.568M 10.016M 4.686M
Begin Period Cash Flow 90.882M 325.703M 26.135M 16.119M 11.433M
End Period Cash Flow 52.012M 90.882M 325.703M 26.135M 16.119M
Total Cash From Operating Activities -110.062M -104.551M -69.83M -54.76M -48.655M
Depreciation 0.759M 0.558M 0.194M -1.103M 0.01M
Other Cashflows From Investing Activities - - - -46.325M -79.3M
Dividends Paid - - - - -
Change To Inventory - - - - -0.443M
Sale Purchase Of Stock 29.14M - 459.335M 108.165M 132.172M
Other Cashflows From Financing Activities 13.844M 3.815M 10.249M 2.936M 1.719M
Capital Expenditures 0.626M 1.147M 2.171M 2.171M 2.171M
Change In Working Capital -2.982M -3.224M 6.384M 0.074M 4.381M
Other Non Cash Items 1.683M 0.399M 0.41M -1.103M 0.184M
Free Cash Flow -110.688M -105.698M -72.001M -54.76M -48.655M

Funds

Sr. No. Name Purchased On Shares
1. Franklin Small Cap Growth SMA 2 years ago 686100
2. iShares Russell 2000 Value ETF 2 years ago 657263
3. Franklin Biotechnology Discv A(acc)USD 2 years ago 533902
4. HBM Healthcare Investments AG Ord 2 years ago 500000
5. iShares Biotechnology ETF 2 years ago 478223
6. Fidelity Extended Market Index 2 years ago 444843
7. State St Russell Sm/Mid Cp® Indx NL Cl C 2 years ago 430594
8. Belfius Equities Cure C Cap 2 years ago 371996
9. Candriam Global Equities Oncology 2 years ago 371996
10. Schwab US Small-Cap ETF™ 2 years ago 359734
11. BlackRock Advantage Small Cap Core Instl 2 years ago 348713
12. Franklin Biotechnology Discovery A 2 years ago 281882
13. Candriam Eqs L Biotech C USD Cap 2 years ago 279402
14. SPDR® S&P Biotech ETF 2 years ago 2416729
15. Vanguard Total Stock Mkt Idx Inv 2 years ago 2211528
16. iShares Russell 2000 ETF 2 years ago 1646202
17. Vanguard Institutional Extnd Mkt Idx Tr 2 years ago 1140481
18. Fidelity Small Cap Index 2 years ago 720433
19. Franklin US Small Cap Growth Equity 2 years ago 686100
20. Franklin Small Cap Growth Adv 2 years ago 686100

Institutions

Sr. No. Name Purchased On Shares
1. BlackRock Inc 2 years ago 7315647
2. Suvretta Capital Management, LLC 2 years ago 6946230
3. EcoR1 Capital, LLC 2 years ago 5806871
4. Vanguard Group Inc 2 years ago 4037691
5. venBio Select Advisor LLC 2 years ago 2980000
6. State Street Corporation 2 years ago 2921810
7. Armistice Capital, LLC 2 years ago 2224000
8. Dimensional Fund Advisors, Inc. 2 years ago 2001754
9. Foresite Capital Management IV, LLC 2 years ago 1849947
10. Artal Group S A 2 years ago 1768056
11. Sofinnova Ventures 2 years ago 1667321
12. Geode Capital Management, LLC 2 years ago 1656009
13. TCG Crossover Management, LLC 2 years ago 1423642
14. Franklin Resources Inc 2 years ago 1353665
15. Morgan Stanley - Brokerage Accounts 2 years ago 1330955
16. Paradigm Biocapital Advisors LP 2 years ago 1262828
17. COMMODORE CAPITAL LP 2 years ago 1248062
18. Assenagon Asset Management SA 2 years ago 1153845
19. Goldman Sachs Group Inc 2 years ago 1063124
20. Prosight Management, LP 2 years ago 950000
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Sponsored Articles

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App